Riluzole

The standard, FDA-recommended dosage for Riluzole in adults with Amyotrophic Lateral Sclerosis (ALS) is 50 mg taken orally every 12 hours. This results in a total daily dose of 100 mg. Clinical data have shown that increasing the dose beyond 100 mg per day does not provide additional therapeutic benefit but does significantly increase the risk of adverse effects, particularly liver enzyme elevations and gastrointestinal distress.

Consistency is vital when taking Riluzole. Patients are encouraged to take their doses at the same time each day (e.g., 8:00 AM and 8:00 PM) to maintain steady levels of the medication in the bloodstream.

Riluzole is not approved for use in pediatric patients. The safety and effectiveness of Riluzole in children and adolescents under the age of 18 have not been established. ALS is an adult-onset disease, and the pharmacological profile of Riluzole in developing biological systems is unknown. If a child accidentally ingests Riluzole, seek emergency medical attention immediately.

Renal Impairment

Specific dosage adjustment guidelines for patients with renal (kidney) impairment are not well-defined. However, since the drug is primarily metabolized by the liver, mild to moderate renal impairment may not require a dose change. In cases of severe renal impairment, healthcare providers will exercise extreme caution and monitor the patient closely for signs of toxicity.

Hepatic Impairment

Riluzole is contraindicated (should not be used) in patients with baseline serum transaminases (ALT/AST) greater than 3 times the upper limit of normal (ULN). For patients with mild hepatic impairment, the drug should be used with significant caution. Because the liver is the primary site of Riluzole metabolism, any decrease in liver function can lead to dangerously high levels of the drug in the body.

Elderly Patients

No specific dosage adjustments are generally required for geriatric patients based solely on age. However, because elderly patients are more likely to have decreased hepatic or renal function and may be taking multiple other medications, doctors typically start with the standard dose but monitor the patient more frequently for side effects.

To ensure the best possible absorption and efficacy, follow these specific administration instructions:

• Timing: Take Riluzole at least 1 hour before or 2 hours after a meal. Food, especially high-fat food, can reduce the amount of medicine your body absorbs.
• Tablets: Swallow the tablet whole with a full glass of water. Do not crush, chew, or break the tablet unless specifically instructed by your pharmacist or doctor, as this may alter the drug's release profile.
• Oral Suspension (Tiglutik): Shake the bottle gently for at least 30 seconds before each use. Use the provided oral syringe to measure the exact 10 mL dose. It can be administered via a feeding tube if necessary.
• Oral Film (Exservan): Place the film on the tongue and allow it to dissolve. Do not chew or swallow the film whole. Do not take with liquids.
• Storage: Store Riluzole at room temperature (68°F to 77°F or 20°C to 25°C), away from moisture, heat, and direct light. Keep the medication out of reach of children and pets.

If you miss a dose of Riluzole, skip the missed dose and take your next dose at the regularly scheduled time. Do not take two doses at once to make up for a missed one. Taking a double dose can increase the risk of serious side effects, such as extreme dizziness or liver toxicity.

Signs of a Riluzole overdose may include severe encephalopathy (brain dysfunction), extreme drowsiness, agitation, or even coma. In some cases, methemoglobinemia (a blood disorder where oxygen cannot be effectively released to tissues) has been reported.

In the event of a suspected overdose, contact your local poison control center or seek emergency medical care immediately. There is no specific antidote for Riluzole; treatment is supportive and focused on managing symptoms.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this could impact the effectiveness of your treatment plan.

Like all medications, Riluzole can cause side effects, although not everyone experiences them. The most frequently reported adverse reactions include:

• Nausea and Gastrointestinal Distress: This is the most common side effect. Patients may feel 'queasy' or have a decreased appetite. This often occurs early in treatment and may subside as the body adjusts.
• Asthenia (Weakness/Tiredness): Many patients report a general feeling of fatigue or lack of energy. Because ALS itself causes weakness, it can sometimes be difficult to distinguish between the disease and the drug effect.
• Decreased Lung Function: Paradoxically, while the drug is meant to help in the long term, some patients may experience a slight decrease in respiratory parameters initially. This must be monitored closely by a neurologist.
• Abdominal Pain: Discomfort or cramping in the stomach area is relatively common.
• Dizziness: Some patients may feel lightheaded, particularly when moving from a sitting to a standing position.

These side effects occur in a smaller percentage of patients but are still well-documented:

• Circumoral Paresthesia: A tingling or 'pins and needles' sensation around the mouth.
• Somnolence: Excessive sleepiness or drowsiness during the day.
• Vomiting: More severe gastrointestinal upset than simple nausea.
• Tachycardia: An abnormally fast heart rate or palpitations.
• Edema: Swelling, particularly in the feet or ankles, caused by fluid retention.

• Anemia: A decrease in red blood cell count, leading to paleness and increased fatigue.
• Exfoliative Dermatitis: A severe skin reaction involving redness and peeling of the skin over large areas of the body.
• Pancreatitis: Inflammation of the pancreas, which presents as severe upper abdominal pain radiating to the back.

> Warning: Stop taking Riluzole and call your doctor immediately if you experience any of the following serious symptoms:

• Hepatotoxicity (Liver Damage): This is the most significant risk associated with Riluzole. Symptoms include yellowing of the skin or eyes (jaundice), dark-colored urine, severe right-sided abdominal pain, or extreme fatigue. Your doctor will perform regular blood tests to check your liver enzymes (ALT and AST).
• Interstitial Lung Disease (ILD): Though rare, Riluzole can cause inflammation in the lungs. Seek help if you develop a new or worsening dry cough, fever, or significant shortness of breath.
• Neutropenia (Low White Blood Cell Count): Riluzole can occasionally lower the number of white blood cells needed to fight infection. Contact your doctor if you develop a fever, chills, sore throat, or mouth sores.
• Severe Allergic Reaction (Anaphylaxis): Signs include hives, difficulty breathing, or swelling of the face, lips, tongue, or throat.

The primary concern with long-term Riluzole use is the cumulative effect on the liver. Because ALS is a chronic condition, patients may be on Riluzole for years. Continuous monitoring of liver function is required for the duration of therapy. There is no evidence that Riluzole causes long-term cognitive impairment or permanent damage to other organ systems, provided that liver and lung health are monitored.

No FDA black box warnings currently exist for Riluzole. However, the warnings regarding liver toxicity are considered 'major' and are featured prominently in the 'Warnings and Precautions' section of the prescribing information. The FDA requires that liver function tests be performed before starting the drug and at regular intervals thereafter.

Report any unusual symptoms or changes in your health to your healthcare provider promptly. Keeping a 'symptom diary' can be helpful for your doctor to determine if a side effect is related to the medication or the progression of ALS.

Riluzole is a potent medication that requires careful medical supervision. It is specifically designed for Amyotrophic Lateral Sclerosis (ALS) and should not be used for other conditions without specialist consultation. The most critical safety aspect of Riluzole therapy is the risk of liver injury, which can be asymptomatic (showing no symptoms) in its early stages. Therefore, adherence to laboratory monitoring schedules is mandatory for all patients.

There are currently no FDA black box warnings for Riluzole. However, the FDA-approved labeling contains significant warnings regarding hepatotoxicity (liver damage) and neutropenia (low white blood cell count).

Hepatotoxicity (Liver Damage)

Clinical trials have shown that Riluzole can cause elevations in serum transaminases (liver enzymes). In most cases, these elevations occur within the first 3 months of treatment. While many cases are mild, severe liver injury and even fatalities have been reported. If ALT levels rise to 5 times the upper limit of normal, the drug must be discontinued immediately.

Interstitial Lung Disease (ILD)

Cases of ILD have been reported in patients treated with Riluzole. If respiratory symptoms develop (such as a dry cough or difficulty breathing), the drug should be stopped until a lung evaluation is performed. If ILD is confirmed, Riluzole must be permanently discontinued.

Neutropenia and Blood Disorders

Patients should be alert for any signs of infection (fever, sore throat). Riluzole can cause a drop in white blood cell counts (neutropenia), which weakens the immune system. If a low white blood cell count is detected, the medication may need to be stopped.

CNS Depression

Because Riluzole can cause somnolence (drowsiness) and dizziness, patients should be cautious when performing tasks that require mental alertness.

To ensure safety, healthcare providers will require the following tests:

• Liver Function Tests (LFTs): This includes ALT, AST, and bilirubin. Typically, these are checked once a month for the first 3 months of treatment, then every 3 months for the remainder of the first year, and periodically thereafter.
• Complete Blood Count (CBC): To monitor for neutropenia or anemia.
• Physical Exams: Regular assessments of respiratory function and muscle strength.

Riluzole may cause dizziness or sleepiness. Do not drive, operate heavy machinery, or engage in dangerous activities until you know how Riluzole affects you. If you feel drowsy or lightheaded, avoid these tasks and consult your doctor.

Avoid or strictly limit alcohol consumption while taking Riluzole. Alcohol is a known hepatotoxin (liver-damaging substance). Combining alcohol with Riluzole significantly increases the risk of severe liver damage. Additionally, alcohol can worsen the dizziness and drowsiness caused by the medication.

There is no evidence of a 'withdrawal syndrome' associated with Riluzole. However, you should not stop taking the medication without discussing it with your neurologist. Stopping the drug will end its neuroprotective benefits, which may lead to a faster progression of ALS symptoms toward respiratory failure.

> Important: Discuss all your medical conditions, especially any history of liver or kidney disease, with your healthcare provider before starting Riluzole. Be sure to mention if you are a smoker, as tobacco use can decrease the effectiveness of the drug.

There are few absolute contraindications for drug combinations with Riluzole, but substances that cause severe liver toxicity should be avoided.

• Hepatotoxic Agents: Drugs known to cause significant liver damage (such as high-dose methotrexate or certain older anti-seizure medications) should not be used concurrently with Riluzole due to the additive risk of liver failure.

CYP1A2 Inhibitors

Since Riluzole is metabolized by the CYP1A2 enzyme, any drug that inhibits this enzyme will cause Riluzole levels to rise, increasing the risk of toxicity. Examples include:

• Ciprofloxacin: A common antibiotic.
• Fluvoxamine: An SSRI used for OCD and depression.
• Enoxacin: An antibacterial agent.
• Cimetidine: A stomach acid reducer.

CYP1A2 Inducers

Conversely, drugs or substances that induce (speed up) the CYP1A2 enzyme will cause Riluzole to be cleared from the body too quickly, reducing its effectiveness. Examples include:

• Rifampin: An antibiotic used for tuberculosis.
• Omeprazole: A proton pump inhibitor (at high doses).
• Barbiturates: Used for seizures or sedation.

• Amitriptyline and Theophylline: These medications are also substrates for CYP1A2. Taking them with Riluzole may lead to competitive inhibition, where the body struggles to process both drugs, potentially raising the levels of both.
• Caffeine: High intake of caffeine can inhibit CYP1A2 and may theoretically increase Riluzole exposure, though moderate consumption is usually acceptable.

• High-Fat Meals: As previously noted, high-fat food significantly reduces the absorption of Riluzole. To ensure the drug works correctly, it should be taken on an empty stomach (1 hour before or 2 hours after eating).
• Charbroiled Foods: Meat cooked at very high temperatures (charbroiled) can induce CYP1A2 enzymes, potentially lowering Riluzole levels.

• St. John’s Wort: This herbal supplement is a potent inducer of many liver enzymes. It may decrease the concentration of Riluzole in the blood, making the treatment less effective.
• Kava and Comfrey: These herbs are known to be hard on the liver. Combining them with Riluzole increases the risk of hepatotoxicity.
• Antioxidants: While often taken by ALS patients, high doses of certain antioxidants should be discussed with a doctor to ensure they do not interfere with Riluzole’s metabolic pathway.

Riluzole does not typically interfere with standard laboratory test results (like glucose or cholesterol tests), but it will directly cause changes in Liver Function Tests (ALT/AST). It is important that the laboratory and your doctors know you are taking Riluzole when they interpret these specific results.

Management Strategy

If you must take a medication that interacts with Riluzole, your doctor may:

1. 1Adjust the dose of Riluzole or the interacting drug.
2. 2Increase the frequency of liver enzyme monitoring.
3. 3Switch you to an alternative medication that does not use the CYP1A2 pathway.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. This includes over-the-counter pain relievers like acetaminophen (Tylenol), which also affects the liver.

There are specific circumstances under which Riluzole must NEVER be used because the risks clearly outweigh any potential benefits:

1. 1Severe Hypersensitivity: Patients who have had a documented severe allergic reaction (anaphylaxis, angioedema, or severe rash) to Riluzole or any of the inactive ingredients in the tablets, liquid, or film must not take the medication. A second exposure could be life-threatening.
2. 2Severe Hepatic Disease: Riluzole is strictly contraindicated in patients who have pre-existing liver disease or baseline liver enzymes (ALT/AST) that are more than 3 times the upper limit of normal. Because the liver is responsible for clearing the drug, a damaged liver cannot process Riluzole, leading to toxic accumulation and potential acute liver failure.
3. 3Active Acute Liver Injury: If a patient is currently experiencing acute hepatitis or other active liver insults, Riluzole should not be initiated.

These are conditions where Riluzole might be used, but only with extreme caution and frequent monitoring:

• Mild to Moderate Hepatic Impairment: If liver enzymes are slightly elevated but below the 3x threshold, the doctor must weigh the neuroprotective benefits against the risk of further liver damage.
• Renal Impairment: While Riluzole is primarily metabolized by the liver, its metabolites are cleared by the kidneys. Patients with significantly reduced kidney function may require more frequent monitoring for side effects.
• Pregnancy and Lactation: Because the effects on a developing fetus or nursing infant are not fully understood, these are considered relative contraindications where the drug is usually avoided unless the benefit to the mother is deemed essential.

There is no well-documented cross-sensitivity between Riluzole and other major drug classes. However, patients who are sensitive to other benzothiazole derivatives (used in some industrial processes or other rare medications) should inform their doctor.

Always provide a full medical history to your neurologist, including any history of hepatitis, heavy alcohol use, or previous drug allergies.

> Important: Your healthcare provider will evaluate your complete medical history, including liver health and current medications, before determining if Riluzole is safe for you.

Riluzole is classified by the FDA as Pregnancy Category C (under the older system). This means that studies in animals have shown adverse effects on the fetus (such as decreased fertility and increased embryolethality), but there are no adequate and well-controlled studies in humans. It is not known whether Riluzole can cause fetal harm when administered to a pregnant woman. Consequently, Riluzole should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Women of childbearing age should discuss contraception with their doctor while taking this medication.

It is not known if Riluzole is excreted in human milk. Many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants (including liver toxicity and neurological effects), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Most clinical guidelines recommend against breastfeeding while taking Riluzole.

As previously stated, the safety and effectiveness of Riluzole in pediatric patients have not been established. ALS is extremely rare in children, and Riluzole is not approved for use in patients under 18 years of age. There is no data regarding how Riluzole might affect growth, development, or the maturing nervous system in children.

Clinical studies of Riluzole included a significant number of patients aged 65 and over. No overall differences in safety or effectiveness were observed between these older patients and younger patients. However, the elderly are generally more likely to have decreased hepatic, renal, or cardiac function.

• Polypharmacy Concerns: Older adults are often taking medications for blood pressure, cholesterol, or diabetes, which may interact with Riluzole or increase the burden on the liver.
• Fall Risk: Because Riluzole can cause dizziness and somnolence, elderly patients should be monitored for an increased risk of falls.

The pharmacokinetics of Riluzole have not been extensively studied in patients with renal failure. However, about 90% of a Riluzole dose is recovered in the urine as metabolites. While the parent drug is metabolized by the liver, the accumulation of metabolites in patients with severe renal impairment (CrCl < 30 mL/min) could potentially lead to unforeseen side effects. Use in this population requires clinical vigilance.

This is the most critical special population for Riluzole.

• Mild Impairment: May result in higher plasma concentrations of the drug.
• Moderate to Severe Impairment: Riluzole clearance is significantly reduced. The drug is contraindicated in those with baseline ALT/AST > 3x ULN.
• Monitoring: For any patient with a history of liver disease, LFTs should be monitored more frequently than the standard protocol (e.g., every 2 weeks for the first month).

> Important: Special populations require individualized medical assessment. Always inform your healthcare team about your age, pregnancy status, and any organ-specific health issues.

Riluzole is a glutamate modulator. Its primary therapeutic action in ALS is thought to be the inhibition of glutamate release from presynaptic terminals. It achieves this by blocking voltage-gated sodium channels (specifically the Nav1.6 subtype), which prevents the repetitive firing of action potentials that lead to neurotransmitter release. Additionally, Riluzole may increase the clearance of glutamate from the synapse by enhancing the activity of excitatory amino acid transporters (EAATs) on astrocytes. By reducing the overall 'glutamatergic tone,' Riluzole protects motor neurons from calcium-mediated apoptosis (programmed cell death) caused by excitotoxicity.

• Dose-Response: Clinical trials evaluated 50 mg, 100 mg, and 200 mg daily doses. While 100 mg (50 mg BID) showed a clear survival benefit, the 200 mg dose provided no additional benefit but significantly increased liver toxicity.
• Onset of Effect: The neuroprotective effects of Riluzole are not immediate. It takes months of consistent use to observe a statistical difference in disease progression.
• Tolerance: There is no evidence that patients develop pharmacological tolerance to the neuroprotective effects of Riluzole over time.

| Parameter | Value |

|---|---|

| Bioavailability | ~60% (decreased by high-fat food) |

| Protein Binding | ~96% (primarily Albumin) |

| Half-life | ~12 hours |

| Tmax | 1.0 to 1.5 hours |

| Metabolism | Hepatic (Primary: CYP1A2; Secondary: CYP2D6) |

| Excretion | Renal (90% as metabolites), Fecal (5%) |

• Molecular Formula: C8H5F3N2OS
• Molecular Weight: 234.2 g/mol
• Solubility: Very slightly soluble in water; freely soluble in methanol and ethylene chloride.
• Description: Riluzole is a white to slightly yellow powder. Chemically, it is 2-amino-6-(trifluoromethoxy)benzothiazole.

Riluzole is the prototypical member of the benzothiazole class of glutamate antagonists. While other drugs target glutamate receptors (like Memantine for Alzheimer's), Riluzole is unique in its focus on inhibiting glutamate release and its specific application in motor neuron disease. It is often categorized as a 'neuroprotective agent' or 'antiglutamatergic.'